SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT. A live webcast of the event will be available in the Investors section o ...

BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management plans to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 11:15 a.m. PST / 2:15 p.m. EST. A live and archived webcast of the pr ...

Core Insights - Rapport Therapeutics is set to present results from its Phase 2a trial of RAP-219 for focal onset seizures at the 2025 American Epilepsy Society Annual Meeting, highlighting new efficacy analyses and treatment effects [1][2]. Company Overview - Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [8]. - The company's lead investigational drug, RAP-219, is designed to selectively target TARPγ8, a receptor associated protein expressed in specific brain regions, potentially offering a differentiated profile compared to traditional neuroscience medications [7][8]. Clinical Trial Details - The Phase 2a trial of RAP-219 will present topline efficacy and safety data, including the drug's effects during the first month of treatment and its consistency in efficacy throughout the treatment period [2][4]. - Additional analyses will cover the impact of baseline disease severity on efficacy outcomes and the effect of RAP-219 on seizure severity [2][6]. Presentation Schedule - The company will host a dedicated Scientific Exhibit Room at the meeting, featuring multiple poster presentations on RAP-219's clinical program [4][5]. - Specific poster sessions are scheduled for December 7 and 8, 2025, detailing various aspects of RAP-219's efficacy and safety [5][6].

Core Insights - Maze Therapeutics is presenting seven studies at the American Society of Nephrology's Kidney Week, focusing on their lead programs MZE782 and MZE829, which target chronic kidney disease (CKD) and phenylketonuria (PKU) [1][2][3] Group 1: Company Overview - Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases [1][7] - The company utilizes its Compass platform to pursue genetically validated targets, integrating variant discovery and functionalization [7] Group 2: Product Pipeline - MZE782 is an oral SLC6A19 inhibitor aimed at treating PKU and CKD, showing a strong safety profile and potential to improve kidney function in Phase 1 trials [2][6] - MZE829 is an oral APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), which affects over one million people in the U.S. [2][4] - The HORIZON trial for MZE829 is currently enrolling patients and aims to provide initial topline results in Q1 2026 [5] Group 3: Research Presentations - Presentations at ASN include studies on the genetic variants of APOL1 in kidney disease, the effects of small molecule inhibitors on dysfunctional signaling, and the impact of SLC6A19 variants on kidney function [3][4] - Specific presentation titles include studies on APOL1 risk variants, SLC6A19 inhibition, and pharmacokinetics of MZE782 [3]

Core Insights - Maze Therapeutics has appointed Hervé Hoppenot as Chairman of the Board, succeeding Charles Homcy, M.D., who will remain on the Board [1][2] - The company is at a pivotal moment with promising first-in-human data for MZE782 and a successful $150 million private placement, positioning it for significant clinical milestones [2][3] - Maze's pipeline includes MZE829, an APOL1 inhibitor in Phase 2 for APOL1-mediated kidney disease, and MZE782, a SLC6A19 inhibitor advancing to Phase 2 for phenylketonuria (PKU) and chronic kidney disease (CKD) [4] Company Overview - Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases [4] - The company utilizes its Compass™ platform to pursue genetically validated targets, integrating variant discovery and functionalization [4] - The leadership of Hervé Hoppenot is expected to be instrumental in advancing the company's therapies and achieving key milestones in 2026 [3]

Core Insights - Rapport Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [3] - The company will participate in the TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17, 2025 [2] Company Overview - Rapport Therapeutics is dedicated to discovering and developing precision medicines, leveraging its RAP technology platform based on pioneering discoveries related to receptor associated proteins (RAPs) in the brain [3] - The lead investigational drug, RAP-219, targets specific regions of the brain and is being pursued for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain [3] - The company is also engaged in preclinical and late-stage discovery programs targeting chronic pain and hearing disorders [3]

Core Viewpoint - Maze Therapeutics has successfully entered into an oversubscribed private placement agreement, raising approximately $150 million to advance its clinical programs and research initiatives [1][4]. Group 1: Private Placement Details - The private placement consists of 4,000,002 shares of common stock priced at $16.25 per share, along with 5,231,090 pre-funded warrants priced at $16.249 each [3]. - The transaction is expected to close on September 12, 2025, pending customary closing conditions [4]. - The placement has attracted both new and existing investors, including notable firms such as Frazier Life Sciences and Janus Henderson Investors [2]. Group 2: Use of Proceeds - Proceeds from the private placement will be utilized to further the development of MZE829 for APOL1-mediated kidney disease, initiate Phase 2 trials for MZE782 targeting phenylketonuria and chronic kidney disease, and support ongoing research and development efforts [4]. - Additional funds will be allocated for working capital and general corporate purposes [4]. Group 3: Company Overview - Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases [8]. - The company's lead candidates include MZE829, an APOL1 inhibitor in Phase 2 development, and MZE782, a SLC6A19 inhibitor also advancing to Phase 2 [8].

Core Insights - Maze Therapeutics announced positive Phase 1 clinical results for MZE782, indicating its potential as a best-in-class therapy for phenylketonuria (PKU) and a first-in-class therapy for chronic kidney disease (CKD) [1][2] Study Design - The Phase 1 trial was a randomized, double-blind, placebo-controlled study involving 112 healthy adult volunteers, assessing single ascending doses (SAD) and multiple ascending doses (MAD) of MZE782 [3][4] - SAD doses ranged from 30 to 960 mg, while MAD doses ranged from 120 to 240 mg twice daily and 120 to 720 mg once daily [3] Safety and Tolerability Profile - MZE782 was well tolerated across all doses, with no serious adverse events reported [5][6] - Mild treatment-related adverse events included headache (4%) and diarrhea (2%) in the SAD cohort, with no adverse events in the MAD cohort [6] Pharmacokinetics - MZE782 demonstrated a favorable plasma pharmacokinetic profile, with consistent absorption and a half-life of 11 hours [7] - Steady-state was achieved by Day 3, supporting a once- or twice-daily dosing regimen for Phase 2 trials [7] Pharmacodynamics - MZE782 produced dose-dependent increases in urinary excretion of phenylalanine (Phe) and glutamine (Gln), confirming target engagement [8][9] - A 42-fold increase in urinary Phe excretion was observed in the 240 mg twice-daily dose cohort after seven days [9] Estimated Glomerular Filtration Rate (eGFR) - MZE782 showed a dose-dependent initial eGFR dip similar to SGLT2 inhibitors, suggesting a potential beneficial effect on kidney physiology [9] - The combined 240 mg BID cohorts demonstrated a change of -11.5 mL/min/1.73m² after seven days, compared to -2.5 mL/min/1.73m² in the placebo cohort [9] Next Steps - The company plans to initiate two Phase 2 proof-of-concept trials for MZE782 in 2026, focusing on plasma Phe reduction in PKU and proteinuria reduction in CKD [10] Company Overview - Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases, utilizing its Compass platform [15]

Core Viewpoint - Rapport Therapeutics is set to announce topline results for the Phase 2a trial of its investigational drug RAP-219, aimed at treating drug-resistant focal onset seizures, during a conference call on September 8, 2025 [1]. Company Overview - Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [3]. - The company’s founders have made significant discoveries regarding receptor associated proteins (RAPs) in the brain, which underpin the RAP technology platform [3]. - The lead investigational drug, RAP-219, is designed to achieve neuroanatomical specificity by selectively targeting a RAP expressed in specific brain regions [3]. - In addition to drug-resistant focal onset seizures, RAP-219 is being explored as a potential treatment for bipolar mania and diabetic peripheral neuropathic pain [3]. - The company is also engaged in preclinical and late-stage discovery programs targeting chronic pain and hearing disorders [3].

Core Insights - Maze Therapeutics has appointed Misbah Tahir as Chief Financial Officer, effective immediately, during a critical phase for the company [1][2] - The company is preparing for significant milestones, including data releases for MZE782 and MZE829 in 2025 and 2026 [2] - Mr. Tahir brings over 20 years of experience in the biopharmaceutical industry, having previously served as CFO at IGM Biosciences and held senior finance roles at other notable companies [2][3] Company Overview - Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases [4] - The company utilizes its Compass platform to pursue genetically validated targets, integrating variant discovery and functionalization [4] - Maze's pipeline includes MZE829, an oral APOL1 inhibitor in Phase 2 development, and MZE782, an oral SLC6A19 inhibitor in Phase 1, targeting chronic kidney disease and phenylketonuria [4] Financial Position - Maze Therapeutics has a strong balance sheet with an expected cash runway extending into the second half of 2027 [3] - The company aims to create significant value for patients and shareholders through its differentiated precision genetics platform and disciplined development approach [3]